These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1028 related items for PubMed ID: 21991951

  • 21. Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
    O'Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP, Lebrun-Frenay C, Mares J, Benamor M, Thangavelu K, Liang J, Truffinet P, Lawson VJ, Wolinsky JS, Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas.
    Neurology; 2016 Mar 08; 86(10):920-30. PubMed ID: 26865517
    [Abstract] [Full Text] [Related]

  • 22. Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis.
    Chan A, de Seze J, Comabella M.
    CNS Drugs; 2016 Jan 08; 30(1):41-51. PubMed ID: 26758290
    [Abstract] [Full Text] [Related]

  • 23. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr 08; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 24. The efficacy and safety of teriflunomide based therapy in patients with relapsing multiple sclerosis: A meta-analysis of randomized controlled trials.
    Xu M, Lu X, Fang J, Zhu X, Wang J.
    J Clin Neurosci; 2016 Nov 08; 33():28-31. PubMed ID: 27492048
    [Abstract] [Full Text] [Related]

  • 25. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
    Chitnis T, Banwell B, Kappos L, Arnold DL, Gücüyener K, Deiva K, Skripchenko N, Cui LY, Saubadu S, Hu W, Benamor M, Le-Halpere A, Truffinet P, Tardieu M, TERIKIDS Investigators.
    Lancet Neurol; 2021 Dec 08; 20(12):1001-1011. PubMed ID: 34800398
    [Abstract] [Full Text] [Related]

  • 26. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
    Comi G, Freedman MS, Kappos L, Olsson TP, Miller AE, Wolinsky JS, O'Connor PW, Benamor M, Dukovic D, Truffinet P, Leist TP.
    Mult Scler Relat Disord; 2016 Jan 08; 5():97-104. PubMed ID: 26856952
    [Abstract] [Full Text] [Related]

  • 27. A randomized crossover study of bee sting therapy for multiple sclerosis.
    Wesselius T, Heersema DJ, Mostert JP, Heerings M, Admiraal-Behloul F, Talebian A, van Buchem MA, De Keyser J.
    Neurology; 2005 Dec 13; 65(11):1764-8. PubMed ID: 16221950
    [Abstract] [Full Text] [Related]

  • 28. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.
    Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, Olsson TP, Benamor M, Bauer D, Truffinet P, Church M, Miller AE, Wolinsky JS, Freedman MS, O'Connor P, TENERE Trial Group.
    Mult Scler; 2014 May 13; 20(6):705-16. PubMed ID: 24126064
    [Abstract] [Full Text] [Related]

  • 29. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis.
    Miller AE, O'Connor P, Wolinsky JS, Confavreux C, Kappos L, Olsson TP, Truffinet P, Wang L, D'Castro L, Comi G, Freedman MS, Teriflunomide Multiple Sclerosis Trial Group.
    Mult Scler; 2012 Nov 13; 18(11):1625-32. PubMed ID: 22723573
    [Abstract] [Full Text] [Related]

  • 30. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
    Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, Cutter G, Mok K, Hsu Y, Xu Y, Weiss MS, Bosco JA, Power SA, Lee L, Miskin HP, Cree BAC, ULTIMATE I and ULTIMATE II Investigators.
    N Engl J Med; 2022 Aug 25; 387(8):704-714. PubMed ID: 36001711
    [Abstract] [Full Text] [Related]

  • 31. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
    Clin Ther; 2008 Jun 25; 30(6):1102-12. PubMed ID: 18640466
    [Abstract] [Full Text] [Related]

  • 32. Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis.
    Comi G, Freedman MS, Meca-Lallana JE, Vermersch P, Kim BJ, Parajeles A, Edwards KR, Gold R, Korideck H, Chavin J, Poole EM, Coyle PK.
    BMC Neurol; 2020 Oct 06; 20(1):364. PubMed ID: 33023488
    [Abstract] [Full Text] [Related]

  • 33. Pathophysiology of multiple sclerosis and the place of teriflunomide.
    Gold R, Wolinsky JS.
    Acta Neurol Scand; 2011 Aug 06; 124(2):75-84. PubMed ID: 20880295
    [Abstract] [Full Text] [Related]

  • 34. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years.
    Confavreux C, Li DK, Freedman MS, Truffinet P, Benzerdjeb H, Wang D, Bar-Or A, Traboulsee AL, Reiman LE, O'Connor PW, Teriflunomide Multiple Sclerosis Trial Group.
    Mult Scler; 2012 Sep 06; 18(9):1278-89. PubMed ID: 22307384
    [Abstract] [Full Text] [Related]

  • 35. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
    Comi G, Filippi M, Wolinsky JS.
    Ann Neurol; 2001 Mar 06; 49(3):290-7. PubMed ID: 11261502
    [Abstract] [Full Text] [Related]

  • 36. Teriflunomide for multiple sclerosis in real-world setting.
    Elkjaer ML, Molnar T, Illes Z.
    Acta Neurol Scand; 2017 Nov 06; 136(5):447-453. PubMed ID: 28321835
    [Abstract] [Full Text] [Related]

  • 37. Teriflunomide: A Review in Relapsing-Remitting Multiple Sclerosis.
    Scott LJ.
    Drugs; 2019 Jun 06; 79(8):875-886. PubMed ID: 31098896
    [Abstract] [Full Text] [Related]

  • 38. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.
    Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959
    [Abstract] [Full Text] [Related]

  • 39. Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
    Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, Martin EC, Dangond F, Syed S, Wolinsky JS, Evobrutinib Phase 2 Study Group.
    N Engl J Med; 2019 Jun 20; 380(25):2406-2417. PubMed ID: 31075187
    [Abstract] [Full Text] [Related]

  • 40. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
    Barkhof F, Hulst HE, Drulovic J, Uitdehaag BM, Matsuda K, Landin R, MN166-001 Investigators.
    Neurology; 2010 Mar 30; 74(13):1033-40. PubMed ID: 20200338
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 52.